Feb 11, 2021 | Published by bit.bio
Ramy Ibrahim, MD, a recognised leader of clinical development in immunotherapy joins bit.bio from the Parker Institute for Cancer Immunotherapy
CAMBRIDGE, SAN FRANCISCO, Thursday 11 February 2021 — biotech firm bit.bio today announces the appointment of Dr Ramy Ibrahim, MD, as Chief Medical Officer. The addition of a Chief Medical Officer is in line with the company’s plans and commitment to transition into a clinical company.
Ramy joins from the Parker Institute for Cancer Immunotherapy where he was Chief Medical Officer and will remain on the board. At the Parker Institute, he spent nearly five years building translational, clinical, and regulatory capabilities from the ground up. Ramy has also spent more than a decade working at major pharma companies, advancing the early stages of immuno-oncology therapies. He is a trained medical oncologist, who conducted bench and clinical immunotherapy research at the cancer vaccine branch of the National Cancer Institute in Bethesda, MD.
Mark Kotter, co-founder and CEO of bit.bio said:
At the heart of bit.bio is a technology, opti-ox™, that was developed in Kotter’s Cambridge research laboratory. It allows for the precise programming and engineering of stem cells to produce consistent, reliable and scalable mature cells of a quality and standard not seen before.
Ramy Ibrahim said:
Read Ramy Ibrahim’s announcement on LinkedIn
bit.bio already has initial cell model products on the market which are being used by researchers for high throughput screening, drug testing and the study of diseases. The next stage will be applying the technology to create a pipeline of cell therapies and Ramy will be part of the leadership team taking that forward. The moonshot goal is to be able to precisely program stem cells into any cell in the human body.
As well as taking up the role of CMO, Ramy will be building bit.bio’s presence in the US and heading up their US operations as they expand.
April Six on behalf of bit.bio
+44 7875 468942